Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma

Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma Cardiovasc Intervent Radiol (2017) 40:1383–1391 DOI 10.1007/s00270-017-1648-7 CLINICAL INVESTIGATION INTERVENTIONAL ONCOLOGY Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma 1 1 2 1 • • • • Lauren S. Chan Daniel Y. Sze George A. Poultsides John D. Louie 1 1 Mohammed A. Abdelrazek Mohammed David S. Wang Received: 16 November 2016 / Accepted: 4 April 2017 / Published online: 21 April 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 Abstract before RE showed decreased levels after treatment (median Purpose Combined hepatocellular-cholangiocarcinoma decrease of 72%, range 13–80%). Best hepatic radiological (cHCC-CC) is a rare mixed cell type primary liver cancer response was 60% partial response and 40% stable disease with limited data to guide management. Transarterial by modified RECIST, and 100% stable disease by RECIST radioembolization with yttrium-90 microspheres (RE) is an v1.1. Poor performance status and the presence of emerging treatment option for both hepatocellular carci- macrovascular invasion were identified as predictors of noma and intrahepatic cholangiocarcinoma. This study reduced survival after RE. explored the safety and efficacy of RE for unre- Conclusion RE appears to be a safe and promising treat- sectable cHCC-CC. ment option for patients with unresectable cHCC-CC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png CardioVascular and Interventional Radiology Springer Journals

Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma

Loading next page...
 
/lp/springer_journal/yttrium-90-radioembolization-for-unresectable-combined-hepatocellular-zxljDE4z7Q
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Subject
Medicine & Public Health; Imaging / Radiology; Cardiology; Nuclear Medicine; Ultrasound
ISSN
0174-1551
eISSN
1432-086X
D.O.I.
10.1007/s00270-017-1648-7
Publisher site
See Article on Publisher Site

Abstract

Cardiovasc Intervent Radiol (2017) 40:1383–1391 DOI 10.1007/s00270-017-1648-7 CLINICAL INVESTIGATION INTERVENTIONAL ONCOLOGY Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma 1 1 2 1 • • • • Lauren S. Chan Daniel Y. Sze George A. Poultsides John D. Louie 1 1 Mohammed A. Abdelrazek Mohammed David S. Wang Received: 16 November 2016 / Accepted: 4 April 2017 / Published online: 21 April 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 Abstract before RE showed decreased levels after treatment (median Purpose Combined hepatocellular-cholangiocarcinoma decrease of 72%, range 13–80%). Best hepatic radiological (cHCC-CC) is a rare mixed cell type primary liver cancer response was 60% partial response and 40% stable disease with limited data to guide management. Transarterial by modified RECIST, and 100% stable disease by RECIST radioembolization with yttrium-90 microspheres (RE) is an v1.1. Poor performance status and the presence of emerging treatment option for both hepatocellular carci- macrovascular invasion were identified as predictors of noma and intrahepatic cholangiocarcinoma. This study reduced survival after RE. explored the safety and efficacy of RE for unre- Conclusion RE appears to be a safe and promising treat- sectable cHCC-CC. ment option for patients with unresectable cHCC-CC.

Journal

CardioVascular and Interventional RadiologySpringer Journals

Published: Apr 21, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off